Skip to main
OCS

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding AG has demonstrated robust potential in its pipeline, particularly with positive Phase 2 data for its OCS-05 candidate in acute optic neuritis, which has led to an expedited timeline for upcoming studies due to favorable interactions with regulatory agencies. The company's lead product, OCS-01, has evidenced promising responder rates in clinical trials, with significant letter gains observed, indicating a strong therapeutic effect that could translate into successful Phase 3 trials. Additionally, the design replication of previous successful trials for the upcoming PIONEER studies further strengthens the outlook for Oculis Holding's advancements in eye care and sight preservation.

Bears say

Oculis Holding AG faces a negative outlook primarily due to the potential for delays in clinical development and regulatory approvals, which could result in prolonged development periods and increased financial burdens. The company's recent financial results indicate a net loss of CHF 16.9 million in Q3 2025, raising concerns about its sustainability in the face of high competition from both existing and emerging therapies targeting similar indications. Additionally, there are significant clinical risks associated with Oculos' development candidates, OCS-01, OCS-02, and OCS-05, which may fail to demonstrate adequate efficacy or safety, further jeopardizing the company's future prospects and market position.

OCS has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 8 analysts, OCS has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.